

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
14 December 2006 (14.12.2006)

PCT

(10) International Publication Number
WO 2006/131519 A1

(51) International Patent Classification:

A61K 31/47 (2006.01) C07D 215/36 (2006.01)
 A61P 31/04 (2006.01) C07D 401/04 (2006.01)
 A61K 31/4709 (2006.01) C07D 405/04 (2006.01)
 C07D 215/22 (2006.01) C07D 401/06 (2006.01)

(21) International Application Number:

PCT/EP2006/062934

(22) International Filing Date: 6 June 2006 (06.06.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

05105023.5 8 June 2005 (08.06.2005) EP
 11/296,918 8 December 2005 (08.12.2005) US

(71) Applicant (for all designated States except US):
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ANDRIES, Koenraad, Jozef, Lodewijk, Marcel** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **KOUL, Anil** [IN/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **GUILLE-MONT, Jérôme, Emile, Georges** [FR/FR]; c/o Johnson & Johnson Pharmaceutical, Research and Development, A division of Janssen-Cilag, Campus Maigremont BP 615, F-27106 Val de Reuil Cedex (FR). **PASQUIER, Elisabeth, Thérèse, Jeanne** [FR/FR]; c/o Johnson & Johnson Pharmaceutical, Research and Development, A division

of Janssen-Cilag, Campus Maigremont BP 615, F-27106 Val de Reuil Cedex (FR). **LANÇOIS, David, Francis, Alain** [FR/FR]; c/o Johnson & Johnson Pharmaceutical, Research and Development, A division of Janssen-Cilag, Campus Maigremont BP 615, F-27106 Val de Reuil Cedex (FR).

(74) Common Representative: **JANSSEN PHARMACEUTICA N.V.**; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

[Continued on next page]

(54) Title: QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS



(57) Abstract: The present invention relates to the use of a compound for the manufacture of a medicament for the treatment of a bacterial infection, said compound being a compound of formula (I) a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof or a N-oxide form thereof, wherein R¹ is hydrogen, halo, polyhaloC₁₋₆alkyl, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkyloxy, Ar or Het; p is an integer equal to 1 or 2; R² is C₁₋₆alkyloxy, C₁₋₆alkyloxyC₁₋₆alkyloxy or C₁₋₆alkyl hio; R³ is C₁₋₆alkyl, Ar, Het or Het1; R⁴ and R⁵ each independently are hydrogen, C₁₋₆alkyl or benzyl; or R⁴ and R⁵ together and including the N to which they are attached may form a

radical selected from the group of pyrrolidinyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolyl, imidazolidinyl, pyrazolidinyl, 2-imidazolinyl, 2-pyrazolinyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridinyl, piperazinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, morpholinyl and thiomorpholinyl, each of said rings may optionally be substituted with C₁₋₆alkyl, halo, polyhaloC₁₋₆alkyl, hydroxy, hydroxyC₁₋₆alkyl, C₁₋₆alkyloxy, amino, mono- or di(C₁₋₆alkyl)amino, C₁₋₆alkyl hio, C₁₋₆alkyloxyC₁₋₆alkyl, C₁₋₆alkyl hioC₁₋₆alkyl or pyrimidinyl; R⁶ is hydrogen, halo, polyhaloC₁₋₆alkyl, C₁₋₆alkyl, C₁₋₆alkyloxy, C₁₋₆alkyl hio; or two vicinal R⁶ radicals may be taken together to form a bivalent radical of formula -CH=CH-CH=CH-; r is an integer equal to 1 or 2; R⁷ is hydrogen, C₁₋₆alkyl, Ar, Het or Het1; provided that the bacterial infection is other than a Mycobacterial infection.



- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- with international search report